EpiPen, Mylan, Heather Bresch, pharmaceutical companies, healthcare, price hike, prices

EpiPen Under Fire for High Price

Money Talking | Aug 26, 2016

Another big pharmaceutical company CEO is in the hot seat.

This time it's Heather Bresch of Mylan Laboratories who's explaining why the price for an EpiPen 2-Pak has gone from about $100 to nearly $600 in just a few years. 

On Thursday, the company said it'd offer a savings card to cover up to $300 for the auto-injector, which is used to reverse life-threatening allergic reactions. But consumers and legislators are still outraged and asking Bresch to go beyond offering subsidies and lower EpiPen's cost.

Mylan joins the ranks of other drug companies like Valeant and Turing, which have been criticized for similar price hikes. Most recently, former Turing CEO Martin Shkreli came under fire for raising the price of a drug for AIDS and cancer patients from $13.50 a pill to $750.

This week on Money Talking, host Charlie Herman talks to Business Insider's Linette Lopez and Rob Cox of Reuters Breakingviews about the EpiPen price hike and the effect expensive drugs have on the country’s healthcare system.

WNYC is funded by sponsors and member donations

Top Stories

Rahm Emanuel Says Israel’s Path Is “Not Sustainable Politically.” Plus, the Critic Richard Brody on “The Odyssey”

A likely Democratic presidential candidate says the U.S. must end unconditional support for Israel. Emanuel explains his proposal for Middle East peace, and his position on trans rights.
The New Yorker Radio Hour |

Smoke-filled skies are new normal for NYC summers, experts warn

Climate change has caused wildfires in Canada to grow more frequent and more intense, which creates a viscous cycle as the blazes pump more carbon into the atmosphere.
Gothamist |

From Subpoenas to Cockroaches: Journalist Intimidation 101

Plus, a documentary about the eBay stalking scandal.
On the Media |

Join us for a live series on what it means to make New York more affordable

We’re holding community events across New York City, “In Conversation: The Affordability Series,” through the rest of the year to explore real solutions to issues affecting millions of New Yorkers.
Gothamist |
YOU ARE ONLINE